This is a past event
This presentation introduces a framework for translating patient-reported outcomes into preference-based measures as exemplified using US SF-6 and SF-12 valuation results.
In the United States, the goal of comparative effectiveness research (CER) is to assist consumers, clinicians, purchasers, and policy makers to make informed decisions that will improve health [outcomes] at both the individual levels and population levels. In our more libertarian system, it is vital that we understand variability in patient experiences and their preferences so that clinical recommendations can be personalized accordingly. This presentation introduces a framework for translating patient-reported outcomes into preference-based measures as exemplified using US SF-6 and SF-12 valuation results. While the debate over quality-adjusted life years (QALYs) endures, CER must continue to produce decision-relevant evidence, particularly to help resolve competitions for scarce health care resources.
Ben Craig is an Assistant Member at the Health Outcomes & Behaviour Moffitt Cancer Centre and has academic appointments at the University of South Florida in the Departments of Economics and Oncologic Sciences. Ben works with the EuroQoL group, and has funding to apply DCEs to estimate new utility weights for the new EuroQoL instrument which is being developed. He is also working in the area of Patient Reported Outcome Measures (PROMs).
For more information on Ben:http://www.moffitt.org/Site.aspx?spid=0D1F2A901260436A882742D8E9E5A4E1&SearchType=Researcher
- Speaker
- Benjamin M. Craig, Moffitt Cancer Center, University of South Florida
- Hosted by
- HERU
- Venue
- IMS Level 7 Conference Room